H. Lundbeck A/S
HLUN-A
Classifica tra le azioni
#2963
H. Lundbeck A/S engages in the research, development, manufacturing, and... H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson’s disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson’s disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. Lundbeck A/S has a strategic research collaboration with Contera Pharma to develop oligonucleotide-based medicines for patients living with serious neurological conditions. The company was founded in 1915 and is headquartered in Valby, Denmark.
Prezzo delle azioni
$7.45
Capitalizzazione di mercato
$6.23B
Variazione (1 giorno)
0.64%
Variazione (1 anno)
35.57%
Paese
DK
Scambia H. Lundbeck A/S (HLUN-A)
Categoria
Healthcare
Cronologia dei frazionamenti azionari per H. Lundbeck A/S (HLUN-A)
L’azione H. Lundbeck A/S (simbolo: HLUN-A) ha subito un totale di 0 frazionamenti.
L’ultimo frazionamento è avvenuto il Oct 21, 2026.
Una quota di HLUN-A acquistata prima di Oct 21, 2026 equivale oggi a 0 quote di HLUN-A.
L’ultimo frazionamento è avvenuto il Oct 21, 2026.
Una quota di HLUN-A acquistata prima di Oct 21, 2026 equivale oggi a 0 quote di HLUN-A.
Elenco dei frazionamenti azionari
| Anno | Frazionamento | Moltiplicatore | Moltiplicatore cumulativo |
|---|---|---|---|
| Non abbastanza dati per le date fornite. | |||
Frazionamenti azionari di aziende simili o concorrenti
| Azienda | Numero di frazionamenti azionari | Moltiplicatore cumulativo | Il paese |
|---|---|---|---|
| 0 | - |
US
|
|
| 0 | - |
SE
|
|
| 0 | - |
FR
|
|
| 0 | - |
IT
|
|
| 0 | - |
US
|
